EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SVA: Sinovac Biotech Ltd

22 Feb 2019
LAST:

6.470

CHANGE:
 0.02		OPEN:
6.490		HIGH:
6.580		ASK:
6.880		VOLUME:
8.2K
CHG(%):
0.31		PREV:
6.490		LOW:
6.250		BID:
128.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Feb 196.4906.5806.2506.4708.2K
21 Feb 196.5006.5106.4706.4907.7K
20 Feb 196.4806.5106.4306.4308.4K
19 Feb 196.4506.5106.4506.4705.6K
18 Feb 196.4306.4306.4306.4300
15 Feb 196.6506.6506.3106.43048.8K
14 Feb 196.5406.6506.5306.6502.8K
13 Feb 196.4906.6506.4806.4805K
12 Feb 196.4806.6906.4206.48017.3K
11 Feb 196.5306.5906.5206.5301.1K

COMPANY PROFILE

Name:Sinovac Biotech Ltd
About:Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:No.39, SHANGDI West Road, Beijing, China, 100085
Website:http://www.sinovacbio.com
CUSIP:P8696W104
CIK:0001084201
ISIN:AGP8696W1045
FIGI:BBG000D0D8P5
   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:6.66
DivYield:8.50
PtB:1.82
PtS:1.83
EBITDA:219.5M
Shares:99.29M
Market Cap:642.44M